Comparison of ceftolozane-tazobactam and ceftazidime-avibactam for the treatment of infections caused by drug-resistant Pseudomonas aeruginosa: An updated systematic review and meta-analysis based on
4 hours ago
- #meta-analysis
- #Pseudomonas aeruginosa
- #antibiotic resistance
- Ceftolozane-tazobactam and ceftazidime-avibactam show comparable efficacy and safety for drug-resistant Pseudomonas aeruginosa infections.
- No significant differences found in all-cause mortality, clinical response, AKI, or emergence of resistance between the two agents.
- Ceftolozane-tazobactam associated with lower risk of recurrent infection within 30-90 days compared to ceftazidime-avibactam (aOR = 0.46).
- Analysis based on 22 studies with 3,361 patients using adjusted data from direct comparisons.
- Moderate-certainty evidence suggests ceftolozane-tazobactam may reduce recurrent infection risk.